- ReShape Lifesciences (RSLS, Financial) receives a USPTO Notice of Allowance for a patent on diabetes neuromodulation technology.
- The technology uses 10 times less energy than traditional methods and is protected until August 2037.
- The company's intellectual property portfolio now includes 63 issued or pending patents.
ReShape Lifesciences (RSLS), a leader in weight loss and metabolic health solutions, has secured a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/069,689. This patent, titled "High-Frequency Low Duty Cycle Patterns for Neural Regulation," provides protection until August 4, 2037, for their innovative Diabetes Neuromodulation system. This system employs the proprietary vBloc™ technology to treat Type 2 diabetes via vagal nerve modulation.
The patented technology is distinguished by its energy-efficient algorithm, which employs discontinuous high-frequency signals with interwoven micro- and millisecond pauses. This method consumes approximately 10 times less energy than traditional continuous signals while maintaining equivalent efficacy. Such efficiency allows for smaller, more compact devices with longer intervals between charges, enhancing patient comfort and adoption.
Preclinical testing on rat vagus nerves has shown that the system's efficacy is equivalent to continuous signals. Furthermore, the technology's compatibility with standard implantable pulse generators means cost-effective development can be achieved, potentially accelerating its market introduction.
ReShape Lifesciences' intellectual property portfolio now comprises 63 issued or pending patents. These cover areas such as vagal neuromodulation, glucose regulation, artificial intelligence, and Bluetooth-enabled applications, building a robust foundation for the company's bioelectronic approach to treating metabolic disorders.
Despite still being in the preclinical phase, the diabetes neuromodulation system represents a promising advancement in personalized medicine. ReShape Lifesciences anticipates that this innovative approach will optimize glucose control in patients with diabetes while potentially reducing reliance on medications and decreasing treatment costs.
